about
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimodClinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyMonoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceActive and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.Rituximab and biosimilars - equivalence and reciprocity.Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.Formulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsNomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.Risk management of biosimilars in oncology: each medicine is a work in progress.Pharmacovigilance Considerations for Biosimilars in the USANew and generic anticoagulants and biosimilars: safety considerations.The US approach to biosimilars: the long-awaited FDA approval pathway.Pharmacovigilance and biosimilars: considerations, needs and challenges.The advent of biosimilars for the treatment of diabetes: current status and future directions.Biosimilars: Hope and concern.Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.Biosimilar biologic drugs: a new frontier in medical care.The surge in biosimilars: considerations for effective pharmacovigilance and EU regulationThe biosimilars journey: current status and ongoing challenges
P2860
Q26740235-5416ACF3-22D6-4644-8249-23D07AE6A997Q26766028-60483F2C-F080-47E7-8E1D-8AD3B8AAB94EQ28078423-FCE4E431-38E4-4619-BC3C-A1D05FE1FDD1Q33419597-42F3A3EF-2D4F-433D-BE00-936659CB1838Q33596879-33A12D3B-840E-4DF0-84BA-AE55508E3E91Q34352446-949C1D55-4E72-4B33-94F2-98CBD0949708Q34612781-0B9F6139-EF3E-48C9-896A-7970276374ADQ35225411-8B568432-DEC6-4B74-83B5-4E9C7841EBAEQ35795287-AAA1BB7A-3CD9-493B-8BE1-777503722B15Q36226309-19504385-230E-4C74-B116-388E6168FDAFQ37821142-57E84A3B-8061-45E7-BD24-56463A1E830BQ38048914-5C8A53D7-D06C-4FC0-8FEC-6EE6413955A3Q38092850-CA49286E-BEA0-4B42-8A8A-8E9D1A932DE0Q38492208-06A9BBA5-44DD-4ADF-8719-2A86522481BDQ38590668-E8A110AB-3139-4AC8-B0B5-09F039D29B0DQ38591272-05CE161D-E797-4D5F-A1F9-0BC66D261CDEQ38592363-80324EF5-2F52-4007-8C39-E4705FDA4C90Q38708927-B36A5CF9-9972-421F-A7EB-84470D52113BQ38726241-114EA09A-6950-4C60-B04E-37C3AB221C8DQ39200937-34B883E8-D483-4DE2-B78B-3C9320902BFDQ57135914-15A7C6CA-C620-4C89-81A3-332E83ACF71DQ57298628-68C49579-07DD-4F23-AE40-7095969D6FE9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biosimilars: pharmacovigilance and risk management.
@en
Biosimilars: pharmacovigilance and risk management.
@nl
type
label
Biosimilars: pharmacovigilance and risk management.
@en
Biosimilars: pharmacovigilance and risk management.
@nl
prefLabel
Biosimilars: pharmacovigilance and risk management.
@en
Biosimilars: pharmacovigilance and risk management.
@nl
P356
P1476
Biosimilars: pharmacovigilance and risk management.
@en
P2093
Begoña Calvo
Leyre Zuñiga
P304
P356
10.1002/PDS.1948
P577
2010-07-01T00:00:00Z